Ergomed logo

ERGO - Ergomed News Story

620p 0.0  0.0%

Last Trade - 14/08/20

Small Cap
Market Cap £300.2m
Enterprise Value £291.3m
Revenue £68.3m
Position in Universe 657th / 1816

RCS - Ergomed plc - Strategic Partnership in Intelligent Automation

Mon 18th May, 2020 7:00am
For best results when printing this announcement, please click on link below:

RNS Number : 1264N  Ergomed plc  18 May 2020





Ergomed Enters Strategic Collaboration to Drive Pharmacovigilance Leadership
in Intelligent Automation


PrimeVigilance collaboration with Automation Anywhere and DataRobot to advance

robotic processes and machine learning



Guildford, UK - 18 May 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the
'Company'), a company focused on providing specialised services to the
pharmaceutical industry, is pleased to announce PrimeVigilance's strategic
collaboration with Automation Anywhere, a global leader in Robotic Process
Automation (RPA) and DataRobot, the leader in enterprise artificial
intelligence (AI), to accelerate the Company's Intelligent Automation


PrimeVigilance, a division of Ergomed, is the leading global specialized
provider of full pharmacovigilance (PV) services, and currently employs over
750 people. By empowering its clients and colleagues with the application of
RPA and Machine Learning (ML), PrimeVigilance will enable clients to improve
quality and consistency within safety databases, as well as productivity.


A successful proof of concept has been completed, and PrimeVigilance will now
implement a cloud software solution to automate specific pharmacovigilance
processes. The productivity gains made possible by working with Automation
Anywhere and DataRobot, are expected to deliver organic growth more
efficiently, with the automation of manual, repetitive processes. Automation
Anywhere's cloud-based RPA on its digital workforce platform combined with
DataRobot's enterprise AI platform will bring new levels of speed and
intelligence to a crucial component of the business, freeing up valuable hours
for highly trained pharmacovigilance professionals to focus on value creation
and problem solving that only humans can address.


This strategic partnership will be part of Ergomed's wider strategy as it
transforms the relationship between its people and technology, enhancing the
Company's creativity, agility and skills for the benefit of its clients and
shareholders. It will enhance Ergomed's existing skills and expertise by
combining human insight and knowledge with the intelligent application of
technology to enhance the speed and precision of analysis and decision making.


Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: "Adoption of the
latest available technologies, including automation and robotic technology
across our pharmacovigilance business, ensures we are able to continue to
offer cutting edge services to our customers. This collaboration provides the
foundation to rapidly identify and automate a wide range of business
processes, enabling clients to maximise quality and consistency within safety
databases as well as increasing productivity."


Prince Kohli, Chief Technology Officer at Automation Anywhere, commented:
"Intelligent Automation can help to unlock valuable human capacity to focus on
innovation-led projects, while reducing costs and shortening the time to
market. Ergomed understands this opportunity, and we're excited to be working
with them and DataRobot to unleash the potential of Intelligent Automation to
enable a better customer experience and faster time to value."


Automation Anywhere Enterprise A2019, was designed from the ground up as a
cloud-native and web-based RPA platform offering lower total cost of ownership
(TCO), increased performance and scalability. It combines advanced RPA,
artificial intelligence (AI) and embedded analytics, enabling enterprises to
digitize business operations, driving scalability, reusability and lowering
operating costs. The company's software bots, which are delivered via the
cloud, work side-by-side with human workers to automate repetitive, mundane
tasks, freeing up valuable human resources to focus on more meaningful work.

"Companies across all sectors and geographies have learned that they can
transform their business by embracing Intelligent Automation," said Dan
Wright, President and COO, DataRobot. "By implementing this technology,
companies can combine the best of human and machine intelligence, drive rapid
automation and enhanced operational efficiency, and experience exponential
returns on their investment. We're excited to have teamed up with Automation
Anywhere to help Ergomed push the boundaries of what's possible."


DataRobot is the leader in enterprise AI, delivering trusted AI technology and
return on investment (ROI) enablement services to global enterprises competing
in today's Intelligence Revolution. DataRobot's enterprise AI platform
democratizes data science with end-to-end automation for building, deploying,
and managing machine learning models.






 Ergomed plc                                             Tel: +44 (0) 1483 402 975
 Miroslav Reljanović (Executive Chairman)
 Richard Barfield (Chief Financial Officer)

 Numis Securities Limited                               Tel: +44 (0) 20 7260 1000
 Freddie Barnfield / Huw Jeremy (Nominated Adviser)
 James Black (Broker)

 Consilium Strategic Communications - for UK enquiries  Tel: +44 (0) 20 3709 5700
 Chris Gardner / Sue Stuart                   
 Matthew Neal / Olivia Manser




 Automation Anywhere   Tel: +44 79 32552473
 Kerry Davis (

 DataRobot            Tel: +1-617-765-4500
 Libby Botsford



About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing, profitable services business
includes an industry leading suite of specialist pharmacovigilance solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
contract research and trial management services under the Ergomed brand (CRO),
and an internationally recognised specialist expertise in orphan drug
development, under PSR. For further information, visit:
( .


About Automation Anywhere

Automation Anywhere is a global leader in Robotic Process Automation (RPA),
empowering customers to automate end-to-end business processes with software
bots - digital workers that perform repetitive and manual tasks, resulting in
dramatic productivity gains, optimized customer experience and more engaged
employees. The company offers the world's only web-based and cloud-native
intelligent automation platform combining RPA, artificial intelligence,
machine learning, and analytics right out of the box, to help organizations
rapidly start and scale their process automation journey. Its Bot Store is the
world's first and largest marketplace with more than 850 pre-built,
intelligent automation solutions. With offices in more than 40 countries and a
global network of 1,500 partners, Automation Anywhere has deployed over 1.8
million bots to support some of the world's largest enterprises across all
industries. For additional information, visit
( .


About DataRobot

DataRobot is the leader in enterprise AI, delivering trusted AI technology and
enablement services to global enterprises competing in today's Intelligence
Revolution. DataRobot's
enterprise AI platform
democratizes data science with end-to-end automation for building, deploying,
and managing machine learning models. This platform maximizes business value
by delivering AI at scale and continuously optimizing performance over time.
The company's proven combination of cutting-edge software and world-class AI
implementation, training, and support services, empowers any organization -
regardless of size, industry, or resources - to drive better business outcomes
with AI.


With a singular focus on AI since its inception, DataRobot has a proven track
record of delivering AI with ROI. DataRobot has offices across the globe and
$431 million in funding from top-tier firms, including New Enterprise
Associates, Sapphire Ventures, Meritech, and DFJ Growth. For more information,
visit (
( , and join the conversation on
( Twitter ( and
( LinkedIn
( .


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact (
 or visit (
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.